Dobutamine in the ICU is used for decreased contractility due to heart failure or cardiac surgical procedures leading to cardiac decompensation.
Dobutamine-norepinephrine, but not vasopressin, restores the ventriculoarterial matching in experimental cardiogenic shock.
Dobutamine is given for heart failure or cardiac surgical procedures that lead to cardiac decompensation.
Low dose dopamine induces hypoxemia in patients with heart failure by impairing both gas exchange and ventilatory responses and thus could precipitate respiratory decompensation in people being weaned from ventilators.
Dobutamine is a type of medication that is used in the ICU to manage low blood pressure.
While the dobutamine drug is safe, it's use requires close monitoring as it has the potential to raise blood pressure and cause arrhythmia.
Dobutamine stimulates the heart muscle and improves blood flow by helping the heart pump better.
Dobutamine is used short-term to treat cardiac decompensation due to weakened heart muscle.
Dobutamine generally decreases cardiac filling pressures and pulmonary vascular resistance.
Dobutamine has a variable effect on heart rate, but can significantly increase heart rate (particularly at the higher concentrations used in stress echocardiography).
Dobutamine Injection is a catecholamine indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
In responders, dobutamine behaved as an inotrope, increasing blood pressure and cardiac index.
In non-responders, dobutamine mainly acted as a vasodilator, since blood pressure decreased, and cardiac index marginally increased.
During dobutamine infusion, the SBP response was 'flat' (<10 mmHg increase or decrease compared with baseline) in 1118 patients (38%).
The SBP increased by 10 mmHg or more in 1064 patients (36%), and decreased by 10 mmHg or more in 786 patients (26%).
The plasma half-life of dobutamine in humans is 2 minutes.
The principal routes of metabolism are methylation of the catechol and conjugation.
In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine.
Dobutamine is also used for short-term treatment of congestive heart failure and for low cardiac output after cardiopulmonary bypass.
In people with chronic low output cardiac failure, dobutamine was superior to dopamine in its ability to increase cardiac output without untoward side effects.